Macrocure prices IPO well below the range at $10


Macrocure, an Israeli biotech developing white blood cell injections to treat hard-to-heal wounds, raised $54 million by offering 5.4 million shares (all primary) at $10, well below the range of $13 to $15. Macrocure plans to list on the NASDAQ under the symbol MCUR. Macrocure initially filed confidentially on 5/5/2014. Credit Suisse and Jefferies & Co. acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: News Headlines , IPOs

Referenced Stocks: MCUR

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by